Impact of abnormal metabolic-immunoinflammatory pathway on splenomegaly in patients with chronic schizophrenia and exploration of risk factors: case-control study - Takeaways - MDSpire

Impact of abnormal metabolic-immunoinflammatory pathway on splenomegaly in patients with chronic schizophrenia and exploration of risk factors: case-control study

  • By

  • Yang Shen

  • Di Wang

  • Zhiyong Li

  • April 2, 2026

  • 0 min

Share

  • 1

    Splenomegaly in chronic schizophrenia patients is associated with higher levels of metabolic and inflammatory markers compared to non-splenomegaly patients.

  • 2

    HbA1c and PANSS negative symptom scores are independently linked to splenomegaly, indicating potential early warning signals.

  • 3

    Aripiprazole use is correlated with lower odds of splenomegaly, suggesting its favorable metabolic profile compared to other antipsychotics.

  • 4

    Chronic schizophrenia patients exhibit a higher incidence of metabolic disorders and somatic diseases than the general population.

  • 5

    The study emphasizes the need for somatic monitoring in schizophrenia to address complications like splenomegaly and improve patient outcomes.

Original Source(s)

Impact of abnormal metabolic-immunoinflammatory pathway on splenomegaly in patients with chronic schizophrenia and exploration of risk factors: case-control study

  • by Yang Shen, Di Wang, Zhiyong Li

  • April 2, 2026

Related Content

Case Study: Rapid Development of Pulmonary Embolism After Initiating Antipsychotic Combination Therapy in an Acute Psychiatric Environment

Real-world use of brexpiprazole during inpatient treatment for schizophrenia: continuation, discontinuation, and concomitant psychotropics

Artificial Intelligence Centrality in Psychotic Delusions and Violence Risk in Forensic Psychiatry: Retrospective Observational Study of Judicial Decisions